Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11172315 | 0.94 | CYP3A4 (0.58) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL9976768 | 0.87 | ACHE (0.62) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL34346 | 0.87 | CYP3A4 (0.65) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3248171 | 0.84 | CYP3A4 (0.61) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL3245843 | 0.84 | CYP3A4 (0.48) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL3326593 | 0.79 | ALDH1A1 (0.65) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL3246649 | 0.77 | MAPT (0.67) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL27537836 | 0.77 | CYP3A4 (0.52) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL4909228 | 0.77 | CYP3A4 (0.52) | CYP3A4TSHRMAPK1MEN1KMT2A | |
| SCHEMBL8738051 | 0.75 | ACHE (0.68) | CYP3A4TSHRMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202997-B2 | Compositions and methods for treating or preventing hypoxic or ischemic injury | IKARIA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202997-B2 | Compositions and methods for treating or preventing hypoxic or ischemic injury | IKARIA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| CN-101240119-B | Carbon black reacted with diazonium salts and products | CABOT CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-1225205-B1 | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010045582-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-1942156-B1 | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2010-04-14 | — | — | EP | disclosed |
| CN-101240119-A | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2008-08-13 | — | — | CN | disclosed |
| EP-1942156-A1 | Carbon black reacted with diazonium salts and products | Cabot Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| CN-1088730-C | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2002-08-07 | — | — | CN | disclosed |
| EP-0799281-B1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORP (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1225205-A2 | Carbon black reacted with diazonium salts and products | CABOT CORPORATION (US) | 2002-07-24 | — | — | EP | disclosed |
| CN-1321708-A | Carbon black reacted with diazols, and products | CABOT CORP (US) | 2001-11-14 | — | — | CN | disclosed |
| US-6042643-A | AS PIGMENT TO COLOR PLASTICS, PAPER, TEXTILE, RUBBER, AQUEOUS INKS | CABOT CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| US-5900029-A | COLORING FIBER OR TEXTILE | CABOT CORPORATION (US) | 1999-05-04 | — | — | US | disclosed |
| US-5851280-A | Reaction of carbon black with diazonium salts, resultant carbon black products and their uses | CABOT CORPORATION (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1175270-A | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 1998-03-04 | — | — | CN | disclosed |
| EP-0799281-A1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018688-A1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | HIF1AN, HIF1A, HYOU1 | CYP3A4 3440/4885TSHR 2862/4885MAPK1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.